Getein Biotech

Getein Biotech Total Assets

The Total Assets of Getein Biotech (603387.SS) as of Nov 2, 2026 is 3.76 B CNY. In the previous year, Total Assets was 3.71 B CNY — a change of 1.31% (higher).

Total Assets

3.76 BCNY

YoY

1.31%

Last updated:

Total Assets of Getein Biotech is 2025 3.76 B CNY. Total Assets of Getein Biotech was 2024 3.71 B CNY. It decreases by 1.31% higher compared to the previous year.

The Getein Biotech Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
1.57 B CNY
Jan 1, 2019
2.01 B CNY
Jan 1, 2020
2.70 B CNY
Jan 1, 2021
3.14 B CNY
Jan 1, 2022
3.68 B CNY
Jan 1, 2023
3.77 B CNY
Jan 1, 2024
3.71 B CNY
Jan 1, 2025
3.76 B CNY
The Getein Biotech Total Assets history
YEARTotal AssetsYoY
3.76 BCNY+1.31%
3.71 BCNY-1.70%
3.77 BCNY+2.56%
3.68 BCNY+17.19%
3.14 BCNY+16.22%
2.70 BCNY+34.49%
2.01 BCNY+27.84%
1.57 BCNY+23.99%
1.27 BCNY+191.79%
434.09 MCNY+32.31%
328.08 MCNY+58.91%
206.45 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Getein Biotech Stock analysis

What does Getein Biotech do? Getein Biotech Inc generates revenue through the sale of in vitro diagnostic reagents and diagnostic instruments. The company offers POCT reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, and hemagglutination reagents. Diagnostic instruments include the FIA 8000 and FIA 8600 immunoquantitative analyzers, Getein 1100 and Getein 1180 fluorescence immunoquantitative analyzers, CM 400 automatic biochemical analyzer, MAGICL 6000 automatic chemiluminescence analyzer, and BHA-5000 five classification blood cell analyzer. The firm also provides testing and agency services. Products are distributed domestically and to overseas markets. The primary buyers of Getein Biotech's products include healthcare facilities, laboratories, and medical institutions within China and international markets. Domestic sales focus on the Chinese healthcare sector, while overseas markets extend to global customers seeking diagnostic solutions. The company's reagent and instrument portfolio targets hospitals, clinics, and diagnostic centers requiring reliable testing equipment and consumables. Getein Biotech's revenue streams are derived from direct sales of its diagnostic reagents and instruments, as well as service-based offerings like testing and agency services. The company's product range caters to both domestic and international healthcare providers, with a strong emphasis on in vitro diagnostic solutions for blood analysis, chemiluminescence, and biochemical testing. The firm's distribution strategy ensures its products reach medical facilities across China and internationally. Getein Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Getein Biotech stock

Total Assets of Getein Biotech is 3.76 B CNY in 2025.

Total Assets of Getein Biotech changed from 3.71 B CNY to 3.76 B CNY, representing a 1.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Getein Biotech since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Getein Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Getein Biotech

All Key Metrics — Getein Biotech